173 related articles for article (PubMed ID: 37484525)
1. Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.
Wang J; Zhang B; Peng L; Liu X; Sun J; Su C; Wang H; Zhao Z; Si L; Duan J; Zhang H; Li M; Zhu B; Zhang L; Li J; Guo J; Luo R; Qiu W; Ye D; Chu Q; Cui J; Dong X; Fan Y; Gao Q; Guo Y; He Z; Li W; Lin G; Liu L; Liu Y; Qin H; Ren S; Ren X; Wang Y; Xue J; Yang Y; Yang Z; Yue L; Zhan X; Zhang J; Ma J; Qin S; Wang B
Ther Adv Med Oncol; 2023; 15():17588359231187205. PubMed ID: 37484525
[TBL] [Abstract][Full Text] [Related]
2. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024.
Wang K; Yang J; Wang B; Liu Q; Wang X; Yin Y; Wang H; Wang S; Hao C; Hao X; Liu Y; Jiang Z; ;
Transl Breast Cancer Res; 2024; 5():9. PubMed ID: 38751677
[TBL] [Abstract][Full Text] [Related]
3. [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)].
Zhou C; Wang J; Bu H; Wang B; Han B; Lu Y; Wang Z; Zhu B; Wang Z; Song Q; Ren S; Lin D; He Y; Hu X; Zhao H; Qin S
Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):65-76. PubMed ID: 32093450
[TBL] [Abstract][Full Text] [Related]
4. Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey.
Zhang L; Wang J; Zhang B; Chu Q; Su C; Wu H; Chen X; Wang B; Yin Y; Zhu B; Sun J
Front Pharmacol; 2021; 12():583126. PubMed ID: 33841138
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
6. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
Pasello G; Pavan A; Attili I; Bortolami A; Bonanno L; Menis J; Conte P; Guarneri V
Cancer Treat Rev; 2020 Jul; 87():102031. PubMed ID: 32446182
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management.
Wang H; Mustafa A; Liu S; Liu J; Lv D; Yang H; Zou J
Front Pharmacol; 2019; 10():1254. PubMed ID: 31708780
[TBL] [Abstract][Full Text] [Related]
9. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.
Wang FH; Zhang XT; Li YF; Tang L; Qu XJ; Ying JE; Zhang J; Sun LY; Lin RB; Qiu H; Wang C; Qiu MZ; Cai MY; Wu Q; Liu H; Guan WL; Zhou AP; Zhang YJ; Liu TS; Bi F; Yuan XL; Rao SX; Xin Y; Sheng WQ; Xu HM; Li GX; Ji JF; Zhou ZW; Liang H; Zhang YQ; Jin J; Shen L; Li J; Xu RH
Cancer Commun (Lond); 2021 Aug; 41(8):747-795. PubMed ID: 34197702
[TBL] [Abstract][Full Text] [Related]
10. UPDATES IN ENDOCRINE IMMUNE-RELATED ADVERSE EVENTS IN ONCOLOGY IMMUNOTHERAPY.
Coniac S; Stoian M
Acta Endocrinol (Buchar); 2021; 17(2):286-289. PubMed ID: 34925584
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Special and Rare Situations: A Brief Review.
Srinivas S; Bajpai J
J Immunother Precis Oncol; 2021 Nov; 4(4):180-184. PubMed ID: 35665024
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology.
He Y; Yu H; Dai S; He M; Ma L; Xu Z; Luo F; Wang L
Genes Dis; 2024 Mar; 11(2):807-818. PubMed ID: 37692505
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
14. Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.
Fang W; Zhao S; Zhang Y; Ma Y; Zhao H; Zhang L
Oncologist; 2019 Feb; 24(Suppl 1):S11-S20. PubMed ID: 30819827
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.
Escoin-Perez C; Blasco S; Juan-Vidal O
Lung Cancer; 2020 Jun; 144():1-9. PubMed ID: 32278215
[TBL] [Abstract][Full Text] [Related]
16. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
Wang W; Wang Q; Xu C; Li Z; Song Z; Zhang Y; Cai X; Zhang S; Lian B; Li W; Liu A; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Xie C; Zhang J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Lan F; Feng H; Wang L; Yao W; Shi X; Huang J; Chen H; Zhang Y; Sun P; Wan B; Pang F; Xu Z; Wang K; Xia Y; Ye M; Wang D; Wei Q; Feng S; Zhou J; Zhang J; Lv D; Gao W; Kang J; Yu G; Liang X; Yu C; Shi L; Yang N; Wu L; Hong Z; Hong W; Fang M; Zhang Y; Lu Y; Wang G; Ma S; Si L; Fang W; Song Y
Thorac Cancer; 2022 Dec; 13(23):3420-3430. PubMed ID: 36268845
[TBL] [Abstract][Full Text] [Related]
17. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions:
Tan S; Day D; Nicholls SJ; Segelov E
JACC CardioOncol; 2022 Dec; 4(5):579-597. PubMed ID: 36636451
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
[TBL] [Abstract][Full Text] [Related]
20. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
